Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Am J Hematol. 2014 Nov;89(11):1051-4. doi: 10.1002/ajh.23827. Epub 2014 Sep 2.
AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.
AL 淀粉样变(AL)较为罕见,在器官功能受损之前,通常无法确诊,即使在已知存在未经治疗的浆细胞异常(PCD)的患者中也是如此。我们共发现 168 例存在 AL 淀粉样变且此前未经治疗的 PCD 患者。最早的症状或体征(s/s)定义为患者报告的首个可归因于 AL 导致的器官功能障碍的症状。将从出现 s/s 到 AL 确诊的时间间隔(Interval-SA)计算在内。在 75%(114/152)的患者中,PCD 诊断先于记录的 s/s 出现,该组的间隔中位数为 10 个月。在 25%(38/152)的患者中,PCD 在 s/s 后确诊,间隔中位数为 20 个月。两组患者从 AL 确诊开始的总体生存率(OS)没有差异。与未预先识别出 PCD 的 AL 患者的对照组相比,患有已知的预先存在的 PCD 的 AL 淀粉样变患者在 AL 诊断时心脏疾病的进展程度较低。预先识别出 PCD 的患者的长期 OS 并没有明显更高。对于无症状 PCD 的患者,应主动询问 AL 淀粉样变的症状和体征,因为及时诊断对 AL 淀粉样变很重要。